2024-02-20 05:50:55
Pfizer Pharmaceuticals Korea (CEO Dong-wook Oh) announced on the 20th that it held a webinar on the topic of ‘Adult Vaccination and the Necessity of PCV13 Vaccination’ for medical staff on January 30th.
This webinar was held to emphasize the importance of adult vaccination and to share the evaluation standards for pneumococcal conjugate vaccines, the distribution of pneumococcal serotypes in domestic adults, and the latest knowledge on vaccination based on real-world clinical evidence (RWE).
Pfizer Pharmaceuticals Korea announced on the 20th that it held a webinar on the topic ‘Adult vaccination and the need for PCV13 vaccination.’
Jinhan Kang, a professor at the Vaccine-Bio Research Institute at the Catholic University of Korea, said, “In the past, only infant-centered vaccination was emphasized, but now adults are no longer free from infectious diseases subject to vaccination,” adding, “Changes in infectious disease epidemiology, overseas travel, and special occupations. He emphasized, “While the need for vaccination is gradually increasing due to various environmental changes, such as the increased risk of exposure to infectious diseases due to work, and as we enter an aging society, vaccination is emerging as an important public health issue even for adults.”
Professor Kang added that pneumococci are currently classified into about 90 serotypes based on their serotype characteristics, and that there are differences in the serotypes that cause invasive pneumococcal infections depending on region, era, use of vaccines, and age. Referring to the WHO report (Technical Report Series, No. 927, 2005), the superiority of a vaccine is not guaranteed unless there is evidence that inclusion of additional serotypes is likely to improve its effectiveness in a particular epidemiological setting. “It cannot be judged solely based on the number of serotypes identified,” he emphasized.
Professor Kang said, “According to the results of surveillance of invasive pneumococcal pneumonia in domestic adults conducted by the Korea Disease Control and Prevention Agency from September 2018 to June 2021, in the case of Non-PCV13/PPSV23 serotypes, 10A, 11A/E and 15B are invasive. “It was the main serotype causing pneumococcal infection, and among the serotypes preventable with protein conjugate vaccines, 3 and 19A were most commonly found,” he explained.
In the subsequent presentation, the importance of actual clinical evidence in evaluating pneumococcal conjugate vaccines was shared. Professor Kang said, “Among the vaccine effectiveness evaluation indicators, immunogenicity results alone are insufficient to predict effectiveness and efficacy, and confirmed through Randomized Controlled Trial (RCT) and Real World Evidence (RWE). “There is a need to consider both the efficacy and effectiveness of the vaccine,” he suggested.
At the end of the presentation, the results of a study on the effectiveness of the 13-valent protein conjugate vaccine, whose effectiveness was confirmed through a real-world effectiveness study, were also introduced. Prevenar 13 was shown to reduce the risk of hospitalization due to vaccine serotype pneumococcal community-acquired pneumonia (CAP) by 72.8% in adults aged 65 years or older.
Song Chan-woo, vice president of Pfizer Korea’s Primary Care division, said, “Pfizer’s pneumococcal vaccine has confirmed its efficacy and effectiveness through actual clinical evidence beyond immunogenicity, and includes all prevalent domestic serotypes. “Based on these strengths, we have been ranked first in sales of pneumococcal vaccines in Korea for 14 consecutive years,” he said. “Pfizer Korea Pharmaceuticals has prepared this vaccine for the first time in 2024 to share the latest knowledge on vaccination and pneumococcal vaccines with medical staff.” “Starting with the webinar, we will always work hard to prevent and eradicate pneumococcal disease this year,” he said.
Send article to Facebook Send article to Twitter Send article to Kakao Story Copy URL Send article to
close
1708409768
#excellence #pneumococcal #conjugate #vaccine #judged #solely #number #serotypes